New radiation technique aims to cut side effects for pelvic cancer patients
NCT ID NCT06650033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a newer type of radiation therapy that adjusts to daily changes in a patient's body shape. The goal is to safely use smaller treatment areas to reduce side effects like bladder and bowel problems. About 280 adults with pelvic cancers (prostate, bladder, rectal, anal, or gynecological) will take part. The study first checks if the new method is practical, then compares side effects with standard radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 280 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Nov 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age \> 18 2. ECOG performance status 0-2 3. Patients receiving curative or adjuvant pelvic radiation including: 1. Prostate cancer where nodal treatment is required 2. Prostate cancer post prostatectomy 3. Bladder cancer 4. Rectal cancer 5. Anal cancer 6. Adjuvant radiotherapy for gynaecological cancers 7. Pelvic Lymph nodes only 4. Ability to understand and the willingness to sign an informed consent Exclusion Criteria: * Hip prosthesis * Patient separation from approximate radiation centre to skin edge \> 24cm, measured on diagnostic scan
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Anal cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Northern Sydney Local Health District
RECRUITINGSt Leonards, New South Wales, 2065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RE-irradiation for isolated FOCal recurrence of prostate cancer with ultrahypofracted SBRT: the RE-FOCUS study - pushing the boundaries of precision and efficacy
- A phase II study of total neoadjuvant mFOLFOX6 plus suvemcitug and enlonstobart with selective omission of pelvic radiotherapy for High-Risk Mid-Rectal locally advanced rectal cancer with MSS status
- Leveraging digital health solutions to collect Patient-Reported outcomes in rectal cancer
- A sharper eye for cancer: new PET tracer targets hidden tumors
- Can a radioactive tracer help surgeons find hidden prostate cancer?
- Steam therapy vs. surgery: can a less invasive fix help men with blocked urine flow?